KZR Stock Forecast 2025-2026
Distance to KZR Price Targets
KZR Price Momentum
10 Quality Stocks Worth Considering Now
Researching Kezar (KZR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on KZR and similar high-potential opportunities.
Latest KZR Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, KZR has a neutral consensus with a median price target of $12.50 (ranging from $7.00 to $18.00). Currently trading at $4.16, the median forecast implies a 200.5% upside. This outlook is supported by 3 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 332.7% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 68.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KZR Analyst Ratings
KZR Price Target Range
Latest KZR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KZR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $9.00 |
| Dec 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $0.00 |
| Nov 14, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $11.00 |
| Oct 18, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $0.00 |
| Oct 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $0.00 |
| Oct 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Downgrade | $0.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Jul 22, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| May 10, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Mar 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Dec 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Nov 27, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Nov 14, 2023 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $2.00 |
| Oct 12, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Oct 5, 2023 | JonesTrading | Catherine Novack | Hold | Downgrade | $0.00 |
| Sep 25, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $20.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $18.00 |
| Aug 11, 2023 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $0.00 |
| May 12, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $19.00 |
| May 12, 2023 | Wells Fargo | Derek Archila | Overweight | Maintains | $13.00 |
Kezar Life Sciences Inc. (KZR) Competitors
The following stocks are similar to Kezar based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kezar Life Sciences Inc. (KZR) Financial Data
Kezar Life Sciences Inc. has a market capitalization of $30.39M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -55.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Kezar Life Sciences Inc. (KZR) Business Model
About Kezar Life Sciences Inc.
Biotechnology company developing therapies for diseases.
Kezar Life Sciences generates revenue through the discovery, development, and commercialization of innovative therapies targeting autoimmune diseases and cancer. The company focuses on creating small molecules that modulate protein homeostasis pathways, aiming to address significant unmet medical needs in the biopharma sector.
Headquartered in South San Francisco, California, Kezar Life Sciences is committed to advancing science that transforms treatment options for chronic and life-threatening diseases, emphasizing the potential for improved patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
55
CEO
Dr. Christopher J. Kirk Ph.D.
Country
United States
IPO Year
2017
Website
www.kezarlifesciences.comKezar Life Sciences Inc. (KZR) Latest News & Analysis
Kezar Life Sciences (NASDAQ: KZR) will present topline Phase 2a results for its PORTOLA study on March 25, 2025, during a conference call featuring key executives and researchers.
Kezar Life Sciences' Phase 2a results for its PORTOLA study could influence stock performance and investor sentiment based on potential therapeutic advancements in autoimmune hepatitis.
Kezar Life Sciences (Nasdaq: KZR) announced positive topline results from its PORTOLA Phase 2a trial for zetomipzomib in autoimmune hepatitis and released its Q4 and year-end 2024 financial results.
Positive Phase 2a results for zetomipzomib signal potential market success in autoimmune hepatitis, boosting investor confidence in Kezar Life Sciences' growth and innovation prospects.
Kezar Life Sciences (Nasdaq: KZR) will present topline results from its PORTOLA Phase 2a trial on March 25, 2025, evaluating zetomipzomib for autoimmune hepatitis treatment.
The announcement of topline results from the PORTOLA Phase 2a trial could significantly impact Kezar Life Sciences' stock price and investor sentiment, depending on the trial outcomes.
Kezar Life Sciences (KZR) will present at a William Blair virtual event on zetomipzomib's development for autoimmune hepatitis and provide a safety update from the PALIZADE Phase 2b trial.
Kezar Life Sciences' KOL event highlights progress in autoimmune hepatitis and safety data from a Phase 2b trial, potentially influencing stock performance and investor sentiment.
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
5 months agoKezar Life Sciences (Nasdaq: KZR) reported Q3 2024 financial results and is advancing the PORTOLA trial, with data expected in H1 2025.
Kezar Life Sciences' progress in the PORTOLA trial and upcoming data release can influence stock performance, reflecting potential advancements in drug development and market opportunities.
GPM is investigating Kezar Life Sciences (Nasdaq: KZR) for potential state law violations by the company and its executives. Shareholders seeking more information can contact GPM.
The investigation into Kezar Life Sciences for potential legal violations could impact stock performance, investor confidence, and lead to financial liabilities.
Frequently Asked Questions About KZR Stock
What is Kezar Life Sciences Inc.'s (KZR) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Kezar Life Sciences Inc. (KZR) has a median price target of $12.50. The highest price target is $18.00 and the lowest is $7.00.
Is KZR stock a good investment in 2025?
According to current analyst ratings, KZR has 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KZR stock?
Wall Street analysts predict KZR stock could reach $12.50 in the next 12 months. This represents a 200.5% increase from the current price of $4.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kezar Life Sciences Inc.'s business model?
Kezar Life Sciences generates revenue through the discovery, development, and commercialization of innovative therapies targeting autoimmune diseases and cancer. The company focuses on creating small molecules that modulate protein homeostasis pathways, aiming to address significant unmet medical needs in the biopharma sector.
What is the highest forecasted price for KZR Kezar Life Sciences Inc.?
The highest price target for KZR is $18.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 332.7% increase from the current price of $4.16.
What is the lowest forecasted price for KZR Kezar Life Sciences Inc.?
The lowest price target for KZR is $7.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 68.3% increase from the current price of $4.16.
What is the overall KZR consensus from analysts for Kezar Life Sciences Inc.?
The overall analyst consensus for KZR is neutral. Out of 6 Wall Street analysts, 3 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $12.50.
How accurate are KZR stock price projections?
Stock price projections, including those for Kezar Life Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.